Top Page
CSL
(Sydney:CSL)
CSL (CSL) vs. iShares MSCI Australia ETF (EWA)
CSL Business Overview & Revenue Model
CSL Earnings Call Summary
CSL Financial Statement Overview
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 15.70B | 15.43B | 14.69B | 13.17B | 10.49B | 10.33B |
| Gross Profit | 7.63B | 7.95B | 7.56B | 6.71B | 5.66B | 5.80B |
| EBITDA | 5.15B | 5.13B | 4.73B | 3.90B | 3.46B | 3.63B |
| Net Income | 1.44B | 3.00B | 2.64B | 2.19B | 2.25B | 2.39B |
Balance Sheet | ||||||
| Total Assets | 37.93B | 39.40B | 38.02B | 54.43B | 41.22B | 18.16B |
| Cash, Cash Equivalents and Short-Term Investments | 1.15B | 2.16B | 1.66B | 2.33B | 15.18B | 1.81B |
| Total Debt | 12.58B | 11.50B | 12.18B | 18.37B | 14.04B | 5.81B |
| Total Liabilities | 17.45B | 18.00B | 18.62B | 27.65B | 20.02B | 9.74B |
| Stockholders Equity | 18.67B | 19.34B | 17.33B | 23.72B | 21.20B | 8.38B |
Cash Flow | ||||||
| Free Cash Flow | 3.18B | 2.54B | 1.51B | 1.35B | 1.90B | 1.97B |
| Operating Cash Flow | 3.76B | 3.56B | 2.81B | 3.87B | 3.62B | 3.65B |
| Investing Cash Flow | -1.18B | -850.00M | -1.26B | -17.61B | -2.26B | -1.68B |
| Financing Cash Flow | -3.04B | -2.24B | -1.28B | 677.92M | 10.58B | -1.41B |
CSL Technical Analysis
CSL Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | $71.20B | 32.58 | 16.36% | 2.58% | 6.07% | 13.75% | |
72 Outperform | AU$502.51M | 15.41 | 15.90% | 0.38% | 7.76% | 1.55% | |
59 Neutral | $1.65B | 54.28 | 54.79% | ― | 12.35% | 26.73% | |
55 Neutral | $2.89B | -19.55 | -18.95% | ― | 198.58% | 3.97% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$567.38M | -6.72 | -35.86% | ― | ― | -19.21% | |
49 Neutral | AU$3.39B | -307.69 | -1.86% | ― | 60.23% | -66.98% |
CSL Corporate Events
CSL Limited has reported an update on its ongoing on-market share buy-back program involving its ordinary fully paid shares listed on the ASX. The company is using this mechanism as part of its capital management strategy, which can influence share supply, ownership structure, and potentially shareholder value.
The latest notification shows that CSL has bought back a total of 3,699,405 shares before the previous trading day and repurchased a further 70,215 shares on the previous day. This daily update signals the continued execution of the buy-back first notified in August 2025, underscoring CSL’s sustained commitment to returning capital and actively managing its balance sheet over time.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$161.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited has provided an updated notification to the ASX on its ongoing on-market share buy-back of ordinary fully paid shares, originally launched in August 2025 as part of its capital management strategy. The latest daily disclosure shows that the company had repurchased a total of 3,620,374 shares before the previous trading day and bought back a further 79,031 shares on that day, signalling continued execution of its buy-back program and potential implications for share count and capital structure.
The update, dated 26 February 2026, confirms CSL is maintaining regular daily reporting of buy-back activity, reinforcing transparency for investors and compliance with ASX requirements. By steadily reducing the number of shares on issue through on-market purchases, CSL may enhance earnings per share over time and signal confidence in its valuation, developments that are likely to be closely monitored by shareholders and market participants.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$164.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited has provided an updated notification on its ongoing on-market share buy-back of ordinary fully paid shares listed under the ASX code CSL. The update, dated 25 February 2026, reports that a total of 3,536,855 shares had been repurchased before the previous trading day, with an additional 83,519 shares bought back on the previous day.
The buy-back, first notified in August 2025 and updated daily, signals CSL’s continued commitment to returning capital to shareholders and potentially optimizing its capital structure. Regular disclosures of cumulative and daily repurchase volumes give investors transparency into the pace and scale of the program, which can influence earnings per share and market perception of the company’s valuation.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$170.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited has provided an updated notification on its on‑market share buy‑back program for its ordinary fully paid shares. The company reported that a total of 3,453,095 shares had been repurchased before the previous trading day, with an additional 83,760 shares bought back on the prior day.
The latest filing, dated 24 February 2026, is part of the company’s ongoing daily disclosure obligations under its buy‑back initiative first notified in August 2025. The continued execution of the on‑market buy‑back signals management’s active capital management strategy, which can support earnings per share and potentially reflects confidence in the company’s valuation.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$170.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited has disclosed a change in the interests of non-executive director Constantine Saroukos, who has indirectly acquired 512 rights under the CSL Limited Non-Executive Director Rights Plan. These rights, held via Solium Nominees (Australia) Pty Ltd as custodian, entitle him to receive one ordinary share per right, with a total consideration of $78,076.19 based on a volume-weighted average price.
The transaction reflects Saroukos contributing a portion of his board fees to acquire equity in CSL, reinforcing alignment between director compensation and shareholder interests. While the change is relatively modest in scale, it underscores the company’s ongoing use of equity-based remuneration structures to incentivize governance stability and long-term commitment from its board members.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$170.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited has reported a change in the interests of non-executive director Cameron Bruce Price under its Non-Executive Director Rights Plan. The filing discloses that Price holds his interest indirectly via Solium Nominees (Australia) Pty Ltd acting as custodian, with additional ordinary shares held by his spouse.
Under the plan, Price acquired 263 rights, each convertible into one ordinary share, for a total consideration of about A$40,105 based on a volume-weighted average price. The rights were funded by contributing a portion of his board fees, reinforcing equity-based alignment between the director and shareholders without altering his direct holding, which remains nil.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$170.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited has updated the market on its ongoing on‑market share buy‑back program for its ordinary fully paid shares. The announcement confirms that, as of 23 February 2026, the company continues to execute daily buy‑backs under a program first notified in August 2025.
The company reported that a total of 3,394,512 shares had been repurchased prior to the latest trading day, with an additional 58,583 shares bought back on the previous day. This sustained buy‑back activity suggests CSL is actively returning capital to shareholders and managing its share base, which may support earnings per share and signal confidence in the company’s valuation.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$170.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited has notified the market of the issue of 775 unquoted rights under its employee incentive scheme, recorded under the ASX security code CSLAL and dated 19 February 2026. These rights are subject to transfer restrictions and will not be quoted on the ASX until those restrictions lapse, underscoring CSL’s ongoing use of equity-based incentives to reward and retain staff while limiting immediate market dilution for shareholders.
The issuance forms part of CSL’s regular capital management and employee remuneration practices rather than a large-scale capital raising. While modest in size, the move reflects continued alignment of employee interests with long-term shareholder value, and signals that CSL is maintaining standard incentive programs to support its operational and strategic objectives.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$170.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited has provided an updated notification to the ASX covering its ongoing on-market share buy-back program for its ordinary fully paid shares. The latest update, dated 20 February 2026, records that the company had repurchased a cumulative 3,325,015 shares prior to the previous day.
The filing also confirms that CSL bought back an additional 69,497 shares on the previous trading day, continuing a program first notified in August 2025. This sustained buy-back activity underscores the company’s capital management strategy and may signal confidence in its valuation, with potential implications for earnings per share and shareholder returns over time.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$169.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited has announced that Paul McKenzie ceased to be a director of the company on 10 February 2026, with this notice serving as his final director’s interest statement to the ASX. At the time of his departure, McKenzie held no CSL securities directly but retained indirect interests through 140,520 performance share units and 27,354 ordinary shares held in custody under the CSL Limited Performance Rights Plan, highlighting ongoing exposure to the company’s equity despite stepping down from the board.
The most recent analyst rating on (AU:CSL) stock is a Hold with a A$188.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited has released slide materials for its half-year results presentation for the period ended 31 December 2025, to be delivered by the chief executive officer and chief financial officer. The event is being webcast, with a recording to be made available on the company’s investor website later in the day, offering stakeholders structured access to the latest financial and operational performance update.
The announcement underscores CSL’s ongoing efforts to maintain transparent communication with investors and the market through real-time briefings and accessible online archives. By centralising these materials on its investor platform, the company supports informed decision-making by shareholders and analysts while reinforcing its engagement practices around key reporting periods.
The most recent analyst rating on (AU:CSL) stock is a Hold with a A$198.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited has declared an interim dividend of USD 1.30 per ordinary fully paid share, covering the six‑month period ended 31 December 2025. The dividend will trade ex‑dividend on 10 March 2026, with a record date of 11 March 2026 and payment scheduled for 9 April 2026, reinforcing the company’s ongoing capital returns to shareholders.
The announcement signals continued confidence in CSL’s cash generation and balance sheet strength, as the board maintains its practice of regular distributions despite a challenging global healthcare environment. Income‑focused investors in the biopharmaceutical group will closely watch how this payout fits into CSL’s broader capital allocation and growth investment plans over the current financial year.
The most recent analyst rating on (AU:CSL) stock is a Hold with a A$198.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL reported half-year underlying NPATA of US$1.9 billion, down 7% in constant currency, with reported net profit plunging 81% to US$401 million as government policy changes, restructuring costs and US$1.1 billion in impairments weighed on results. Revenue fell 4% to US$8.3 billion, driven by weaker immunoglobulin and albumin sales, including a sharp hit from Chinese policy changes and Medicare Part D reforms, although haemophilia products and the newly launched ANDEMBRY posted solid growth.
Despite the earnings slump, CSL said its transformation program is progressing well, having already achieved about 60% of targeted FY26 cost savings through R&D and infrastructure reductions and integration of Behring and Vifor commercial teams. Backed by strong cash flow and a robust balance sheet, the company expanded its share buy-back to US$750 million, committed around US$1.5 billion to expand U.S. plasma manufacturing and maintained FY26 guidance for modest revenue and NPATA growth, underscoring confidence in a stronger second half led by Ig, albumin and new products.
The most recent analyst rating on (AU:CSL) stock is a Hold with a A$198.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited reported a weaker first half for the period ended 31 December 2025, with total revenue slipping 2% year-on-year to US$8.33 billion and reported net profit after tax plunging 80% to US$401 million. Underlying NPATA, which strips out amortisation of acquired IP and significant one-off items, declined a more modest 6% to US$1.95 billion, reflecting underlying business pressures despite continued profitability.
On a constant-currency basis, revenue fell 4% and NPAT dropped 81%, underscoring the extent of the earnings deterioration when currency effects are removed. Earnings per share mirrored the headline profit decline, with basic EPS down 80%, while underlying NPATA per share fell 6%, and the board maintained an unfranked interim dividend of US$1.30 per share, signaling an ongoing commitment to shareholder returns despite the sharp profit contraction.
The most recent analyst rating on (AU:CSL) stock is a Hold with a A$198.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL has announced the retirement of Chief Executive Officer and Managing Director Paul McKenzie, with long‑time company executive and current non‑executive director Gordon Naylor appointed as interim CEO and MD effective 11 February. The leadership change follows McKenzie’s seven years with CSL, including three as CEO during which he steered the group through COVID‑19 disruptions, expanded plasma collection, launched new therapies such as HEMGENIX for haemophilia B and ANDEMBRY for hereditary angioedema, and advanced large‑scale operational transformation initiatives.
Chair Brian McNamee highlighted Naylor’s 33‑year history in senior roles at CSL, including as CFO and President of Seqirus, where he helped build the company’s global plasma and vaccine footprint and led a turnaround of the influenza business. The Board has given Naylor full authority to lead while it conducts a search for a permanent chief, signalling a focus on continuity in executing CSL’s strategic transformation, sustaining R&D investment and delivering growth for patients, public health systems and shareholders.
The most recent analyst rating on (AU:CSL) stock is a Hold with a A$198.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited has notified the market that 59,992 conditional rights (ASX code: CSLAL) have lapsed after the performance or vesting conditions attached to those rights were not met or became incapable of being satisfied, effective 4 February 2026. The lapse reduces the pool of potential future CSL shares that could be issued under equity incentive arrangements, marginally tightening the company’s prospective share capital base and signalling that specific performance or service hurdles for those rights were not achieved.
The most recent analyst rating on (AU:CSL) stock is a Hold with a A$199.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited has scheduled the release of its 2026 half-year financial results for Wednesday, 11 February 2026, underscoring its regular reporting cadence to the market. The company will brief investors and analysts via a webcasted presentation at 10:00am AEDT that day, with results materials and a recording to be made available through the investor section of its website, providing stakeholders with detailed access to the group’s interim performance and outlook.
The most recent analyst rating on (AU:CSL) stock is a Hold with a A$199.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited has informed the market that 34,261 conditional rights (security code CSLAL) have lapsed after the performance or vesting conditions attached to them were not satisfied or became incapable of being met, effective 7 January 2026. The cessation of these rights results in a small reduction in potential future issued capital and reflects routine adjustments to CSL’s equity-based incentive structures, with negligible direct impact on the company’s overall capital position but relevance for holders and participants in its share-based remuneration plans.
The most recent analyst rating on (AU:CSL) stock is a Hold with a A$188.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited has announced an update on its ongoing on-market share buy-back program, revealing that it repurchased 65,217 shares on the previous day, bringing the total number to 2,955,365 shares. This buy-back initiative is part of CSL’s broader strategy to optimize capital management, potentially enhancing shareholder value and reinforcing its market position in the pharmaceutical sector.
The most recent analyst rating on (AU:CSL) stock is a Hold with a A$188.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited has announced an update on its ongoing share buy-back program, revealing that a total of 2,773,525 ordinary fully paid securities have been repurchased before the previous day, with an additional 46,950 securities bought back on the previous day. This buy-back initiative is part of CSL’s strategy to manage its capital structure effectively, potentially enhancing shareholder value and reinforcing its market position.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$256.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited announced a daily update on its ongoing on-market buy-back program, revealing the repurchase of 36,199 ordinary fully paid securities on the previous day, bringing the total number of securities bought back to 2,685,172. This buy-back initiative is part of CSL’s strategy to optimize its capital structure and enhance shareholder value, potentially impacting its market positioning and investor relations positively.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$256.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited has announced an update on its ongoing on-market buy-back program. As of December 10, 2025, the company has bought back a total of 2,634,260 ordinary fully paid securities, with an additional 50,912 securities purchased on the previous day. This buy-back initiative is part of CSL’s strategy to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$256.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited has announced an update on its ongoing on-market buy-back program, with a total of 2,604,378 ordinary fully paid securities bought back before the previous day and an additional 29,882 securities bought back on the previous day. This buy-back initiative is part of CSL’s strategy to optimize its capital structure and return value to shareholders, potentially enhancing its market position and demonstrating confidence in its financial health.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$256.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited has announced a daily update on its ongoing on-market buy-back program, revealing that a total of 2,551,319 ordinary fully paid securities have been bought back prior to the previous day, with an additional 53,059 securities acquired on the previous day. This buy-back initiative reflects CSL’s strategic efforts to manage its capital structure and potentially enhance shareholder value, indicating a proactive approach in optimizing its financial operations.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$256.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited announced the cessation of 32,733 securities due to the lapse of conditional rights, as the conditions were not met or became incapable of being satisfied. This announcement may impact CSL’s capital structure and could have implications for stakeholders, reflecting the company’s ongoing adjustments in managing its securities and market positioning.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$256.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited has announced an update regarding its ongoing share buy-back program. As of December 5, 2025, the company has repurchased a total of 2,551,319 ordinary fully paid securities, with 41,657 bought back on the previous day. This buy-back initiative is part of CSL’s strategy to optimize its capital structure and return value to shareholders, which can have implications for the company’s market positioning and investor relations.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$256.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited has announced an update regarding its ongoing on-market buy-back program, with a recent purchase of 42,359 ordinary fully paid securities. This buy-back initiative, which began on August 20, 2025, is part of CSL’s strategy to optimize its capital structure and potentially enhance shareholder value, reflecting the company’s commitment to maintaining a balanced approach to capital management.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$283.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited has announced the appointment of Gordon Naylor as a director, effective December 1, 2025. This appointment is accompanied by the disclosure of Naylor’s interests in CSL securities, including 39,719 ordinary shares directly held and 54,992 shares held indirectly through Netwealth Investments Limited. This move is significant for CSL as it strengthens its leadership team with Naylor’s expertise, potentially impacting its strategic direction and stakeholder confidence.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$283.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited announced the issuance and conversion of unquoted equity securities, specifically 11,594 ordinary fully paid shares, effective from December 1, 2025. This move is part of the company’s strategic financial operations, potentially impacting its capital structure and offering insights into its ongoing growth and investment strategies.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$283.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.